Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
June 23rd, 2023
Utilizing an immunocompetent, autochthonous tumor model driven by common patient mutations for preclinical testing is critical for immunotherapeutic testing. This protocol describes a method to generate brain tumor mouse models using electroporation-based delivery of plasmid DNA that represent common patient mutations, thus providing an accurate, reproducible, and consistent mouse model.
The technique focuses on modeling patient mutation profiles of glioblastoma in the immunocompetent mouse model and how these different mutations are influencing the tumor microenvironment and response to treatment. Genomic and single-cell sequencing identify that the genetic driver mutations of glioblastoma are associated with the aggressiveness of cancer and components of the tumor microenvironment such as the immune cell population. Glioblastoma mouse models in preclinical trials show great success with immunotherapy, leading to curative results and no sign of tumor growth after treatment.
However, these effects are not reflected in patients for outcome or survival. This protocol recapitulates patient tumor mutation profiles of glioblastoma in the immunocompetent mouse model, allowing gradual autochthonous tumor growth and better prediction of treatment efficacy, especially with immunotherapy. This modeling system integrates DNA plasmids into the genome through electroporation of immunocompetent mice.
It avoids the use of viruses and transplanting thousands of tumor cells, both of which can have their own immune effects, confounding downstream results. Utilizing an immunocompetent mouse model that recapitulates patient mutation profiles allows for a more accurate assessment of treatment outcomes, preventing the laborious task of taking false positive results to the clinic. To begin, place the anesthetized mouse pup on the table in the ventral position.
Pull the back of the pup's head slightly to visualize the cranial skull sutures through the skin. Find lambda on the skull. The ventricle or injection site will be visible midway between lambda and the eye.
At a perpendicular angle, pierce the skin with a glass pipette tip. An initial resistance and slight concave indentation will be observed. Once pierced, hold the tip in place and press the microinjector foot pedal once to inject one microliter of the plasmid mix.
Begin electroporation-based DNA plasmid delivery by placing a square piece of paraffin film on the table and squeezing the electrode gel on top of the film. Then apply a generous amount of the electrode gel on each paddle to cover the electrode paddles completely. Next, hold the pup microinjected with the plasmid DNA mix in the non-dominant hand, keeping the fingers behind the head.
To position the pup's head for electroporation, gently slide a finger on the next dorsal side posterior to the head, and position the positive electrode outside the head where the ventricle is targeted. Place the electrode over the pup's eye and lightly squeeze the electrode paddles on the rostral part of the pup's head. Press the electrode foot pedal to start the electroporation.
With each pulse, rotate the electrode paddles slightly in a counterclockwise direction so the positive paddle moves towards the top of the head. After the final pulse, remove the paddles and place them aside. Mice were moribund by five months post-electroporation with full tumor growth detected through the reporter protein and histological analysis.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol describes a method for generating brain tumor mouse models that accurately represent common patient mutations in glioblastoma. By utilizing an immunocompetent, autochthonous tumor model, researchers can better predict treatment efficacy, particularly for immunotherapy.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Immunotherapy
Background
- Glioblastoma is characterized by aggressive cancer behavior.
- Genetic driver mutations influence tumor microenvironment and treatment response.
- Current preclinical models often fail to predict patient outcomes.
- Immunocompetent models provide a more accurate representation of human disease.
Purpose of Study
- To create a mouse model that mimics patient glioblastoma mutations.
- To study the impact of these mutations on tumor growth and treatment response.
- To enhance the predictive power of preclinical trials for immunotherapy.
Methods Used
- Electroporation-based delivery of plasmid DNA.
- Integration of DNA plasmids into the genome of immunocompetent mice.
- Gradual autochthonous tumor growth modeling.
- Genomic and single-cell sequencing for mutation profiling.
Main Results
- Successful modeling of patient mutation profiles in glioblastoma.
- Identification of immune cell populations associated with tumor behavior.
- Demonstrated efficacy of immunotherapy in preclinical trials.
- Highlighted discrepancies between mouse models and patient outcomes.
Conclusions
- The developed model provides a reliable platform for testing immunotherapeutic strategies.
- It allows for better understanding of tumor microenvironment interactions.
- Future studies can leverage this model to improve patient treatment strategies.
Frequently Asked Questions
Executive Industry Relevance
Electroporation-based delivery of patient-specific mutation signatures into immunocompetent mouse neural precursor cells enables highly predictive, autochthonous brain tumor models for preclinical immunotherapy evaluation. This approach addresses the translational gap between standard cell line xenografts and clinical outcomes by recapitulating the tumor microenvironment and immune contexture. The model supports risk-adjusted advancement of immuno-oncology assets by providing more clinically relevant efficacy and mechanistic data.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of glioblastoma driver mutations and their impact on tumor biology in vivo.
- Supports functional validation of genetic targets within an immunocompetent, disease-relevant system.
- Facilitates mechanistic de-risking by modeling patient mutation profiles and immune interactions.
Screening & Assay Development
- Provides a platform for evaluating immunotherapeutic agents in a context that mirrors patient tumor-immune dynamics.
- Delivers reproducible, quantitative tumor growth and immune cell population readouts for compound assessment.
- Supports assay standardization by avoiding confounding effects of viral vectors or cell transplantation.
Translational & Preclinical Research
- Aligns preclinical efficacy testing with patient-relevant mutation signatures and immune microenvironments.
- Enables continuity from discovery through preclinical validation for immuno-oncology programs.
- Improves predictive confidence for clinical translation by modeling gradual, endogenous tumor development.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies and translational immunotherapy evaluation.
- Discovery Biology: Supports hypothesis testing on mutation-driven tumorigenesis and immune modulation.
- Screening: Provides quantitative, reproducible tumor and immune cell metrics for candidate prioritization.
- Analytics: Enables genomic and single-cell sequencing outputs to compare mutation effects and treatment responses.
- Translational Research: Facilitates alignment with patient biomarker profiles and immune signatures.
- Enterprise Reuse: Offers a reusable, modular platform for diverse mutation and treatment combinations.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in immuno-oncology research.
- Operational Value: Standardizes tumor modeling without viral or transplantation confounders, enhancing reproducibility.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by filtering out false positives before clinical trials.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of immunotherapeutic candidates.
Implementation Considerations
- Requires expertise in neonatal mouse handling, microinjection, and electroporation techniques.
- Needs access to electroporation equipment and genomic analysis infrastructure.
- Demands cross-team standardization for reproducible tumor induction and data collection.
- Adaptation may be needed for different mutation signatures or tumor subtypes.
- Practical limitations include technical skill requirements and model development timelines.
